

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Van der Ploeg Leonardus H.T.</u>			2. Issuer Name and Ticker or Trading Symbol <u>RHYTHM PHARMACEUTICALS, INC. [RYTM]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Scientific Officer</u>			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>05/28/2019</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person			
<u>222 BERKELEY STREET, SUITE 1200</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)						
(Street)	<u>BOSTON</u>	<u>MA</u>	<u>02116</u>						
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/28/2019		M		9,860	A	\$4.59	52,199	D	
Common Stock	05/28/2019		M		140	A	\$6.14	52,339	D	
Common Stock	05/28/2019		S		10,000	D	\$25.38 ⁽¹⁾	42,339	D	
Common Stock	05/29/2019		M		5,000	A	\$4.59	47,339	D	
Common Stock	05/29/2019		S		5,000	D	\$25.51 ⁽²⁾	42,339	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option (Right to Buy)	\$4.59	05/28/2019		M		9,860		(3)	11/16/2025	Common Stock	9,860	\$0	23,611	D	
Employee Stock Option (Right to Buy)	\$6.14	05/28/2019		M		140		(4)	04/04/2027	Common Stock	140	\$0	55,290	D	
Employee Stock Option (Right to Buy)	\$4.59	05/29/2019		M		5,000		(3)	11/16/2025	Common Stock	5,000	\$0	18,611	D	

Explanation of Responses:

- This transaction was executed in multiple trades at prices ranging from \$25.01 to \$26.10, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$25.18 to \$26.02, inclusive; the price reported above reflects the weighted average sale price. Mr. Van der Ploeg hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015.
- The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017.

/s/ Hunter S. Smith, attorney-in-fact for Leonardus H.T. Van der Ploeg 05/30/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.